(b) and (c) Information would be collected from the Ministry of Health and laid on the table of the House.

Rectifyng the Mape System

2220. SHRI ASHOK NATH VERMA:
SHRI DHULESHWAR MEENA:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether it is a fact that the present system of Maximum Allowable Post Manufacturing Expenses (MAPE) is wrong;

(b) whether it is a fact that under the present system of pricing the same mape is allowed on small and high dose drug;

(c) whether it is a fact that due to this the industry is concentrating towards high dose formulations thus ignoring essential medicines; and

(d) if so, what steps have been taken to rectify the present system?

THE MINISTER OF PETROLEUM AND CHEMICALS ((SHRI M. S. GURUPADASWAMY): (a) and (b) The Maximum Allowance Post Manufacturing Expenses (MAPE) which is 75 per cent for Category-I and 100 per cent for Category-II formulations, is based on the measures announced in 1986 by the Government for Rationalisation, Quality Control and Growth of Drugs and Pharmaceuticals Industry in India.

(c) and (d) The entire drug policy is under review.

Production of Medicines by Small scale Sector.

2221. SHRI ASHOK NATH VERMA:
SHRI DHULESHWAR MEENA:

Will the Minister of PETROLEUM & CHEMICALS be pleased to state:

(a) whether it is a fact that small scale units have been totally exempted from price control;

(b) whether it is also a fact that the turn over of several small scale units is higher than the organised sector;

(c) whether it is a fact that organised sector is using small scale units as a tool directly and indirectly in flouting Drug Prices Control Order;

(d) whether it is a fact that his Ministry is aware of such instances;

(e) if so, what are the detais thereof;

(f) whether it is also a fact that small scale sector units are printing high prices and offering his discounts;

(g) whether it is a fact that such a step has discouraged investment;

(h) whether his Ministry has made any study of this aspect; and

(i) if so, the details thereof and what steps have been taken to safeguard consumer interest?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Under the Drugs (Prices Control) Order, 1987, scall scale sector units have been exempted from price control in respect of Category II formulations subject to ful-

filment of conditions contained in Order S.O. 719 (E)/21-7-1988.

(b) Sales turn over of individual units are not monitored by this Department.

(c) to (e) Yes, Sir. Some such instances have come to the notice of the Government, details of which are given in the enclosed (*See* below) statement.

(f) to (i) Under the Drugs (Prices Control) Order, 1987, small scale sector units are free to charge their own prices in respect of Category II and decontrolled formulations However, as a part of the review of the drug policy, the question of continuing the facility of price exemption to Small Scale Sector Units will also be looked into.

Statement

Sl. No.	Name of the Company's involved	Name of product
1	M/s. Carews/M/s. Rousel	Combiflam tablets
2	M/s. Novocare/M/s. Alembic . . .	Magadol tablets
3	M/s. Ultim/M/s. Wockhardt . . .	Proxyion range of formulations
4	M/s. Celsus/M/s. Wockhardt . . .	Ibodex Capsules
5	M/s. Vax Instt. Lab/Albert David . .	Anaflam Tablets
6	M/s. Denis Pharmacy/M/s. May and Baker .	Flagyl Injections.

Recovery of unintended benefit from drugs companies

2222. SHRI SYED SIBTEY RAZI: Will the Minister of PETROLEUM AND CHEMICALS be peased to state:

(a) whether it is a fact that his Ministry has taken a decision to recover the unintended benefit assessed as arrears of land revenue, from those companies who refuse to deposit the same;

(b) if so, what are the names of the companies whose liabilities have been assessed and what is the response in regard to deposit of amount due from each;

(c) whether his Ministry has referred any case to the Collector to recover the amount as arrears of land revenue; and

(d) if so, what are the details thereof?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) In case of those companies who refuse to deposit the amounts due from them, law would take its own course including recovery as arrears of land revenue.

(b) Details asked for have already been furnished in reply to Rajya Sabha Un-Question No. 1321 answered on 20th August, 1990. M/s. Glaxo India Limited and M/s. Lyka Labs., have filed writ petitions in the High Court. M/s. Ethnor Ltd., M/s. German Remedies, M/s. Nicholas and M|s. Parke Davis have deposited further amounts into the Drug Prices Equalisation Account.

(c) No case has been referred to the collector for recovery as an arrears of land revenue recently.

(d) Does not arise in view of reply to (c) above.